Raymond James & Associates Pds Biotechnology Corp Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Raymond James & Associates holds 11,731 shares of PDSB stock, worth $25,808. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,731
Previous 13,852
15.31%
Holding current value
$25,808
Previous $40,000
10.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding PDSB
# of Institutions
64Shares Held
4.32MCall Options Held
253KPut Options Held
70.4K-
Vanguard Group Inc Valley Forge, PA1.52MShares$3.35 Million0.0% of portfolio
-
Black Rock Inc. New York, NY487KShares$1.07 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA415KShares$913,2480.0% of portfolio
-
Inspirion Wealth Advisors, LLC344KShares$757,6660.18% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny234KShares$515,2590.0% of portfolio
About PDS Biotechnology Corp
- Ticker PDSB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,458,700
- Market Cap $62.6M
- Description
- PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...